Relay Therapeutics and Sanjiv Patel News

This is selected news for Relay Therapeutics and Sanjiv Patel, which are filed under Sectors / Healthtech and People, respectively.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/12/2022 Sanjiv Patel Sells 28,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock
Relay Therapeutics, Inc. (NASDAQ:RLAY ‚Ai Get Rating) CEO Sanjiv Patel sold 28,000 shares of the company's stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $20.00, for a total transaction of $560,000.00. Following the completion of the transaction ...
zolmax.com
11/12/2022 Sanjiv Patel Sells 14,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - Ticker Report
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of the stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $20.18, for a total transaction of $282,520.00. Following the transaction, the chief executive officer now owns 254,554 ...
Ticker Report
11/11/2022 Sanjiv Patel Sells 14,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - Slater Sentinel
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of the firm's stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $20.18, for a total transaction of $282,520.00. Following the transaction, the chief executive officer now ...
slatersentinel.com
11/11/2022 Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 28,000 Shares - Financial News Live
Relay Therapeutics, Inc. (NASDAQ:RLAY ‚Ai Get Rating) CEO Sanjiv Patel sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $20.00, for a total value of $560,000.00. Following the completion of the sale ...
finnewslive.com
11/3/2022 Relay Therapeutics Reports Third Quarter 2022 Financial
... European Society for Medical Oncology (ESMO) Congress $1.1 billion in cash, cash equivalents and investments at the end of third quarter 2022 CAMBRIDGE, Mass., ‚Ai Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today ...
Globe Newswire
11/3/2022 Relay Therapeutics (RLAY) Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
... financial results and recent corporate highlights. ‚AuWe continue to deliver on our execution focus for 2022 and the third quarter uniquely exemplified this,‚Au said Sanjiv Patel, M.D., Relay Therapeutics‚Ao president and chief executive officer. ‚AuWe presented interim data at the ESMO Congress that demonstrate an 88% overall response ...
researchpool.com
10/16/2022 Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $296,520.00 in Stock - Watch List News
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of the firm's stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of $21.18, for a total value of $296,520.00. Following the transaction, the chief executive officer now ...
watchlistnews.com
10/14/2022 Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 14,000 Shares
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of Relay Therapeutics stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $21.18, for a total transaction of $296,520.00. Following the completion of the transaction, the chief executive ...
Ticker Report
10/14/2022 Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $296,520.00 in Stock - Financial News Live
Relay Therapeutics, Inc. (NASDAQ:RLAY ‚Ai Get Rating) CEO Sanjiv Patel sold 14,000 shares of the stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $21.18, for a total value of $296,520.00. Following the completion of the transaction, the chief executive officer ...
finnewslive.com
9/18/2022 Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $328,580.00 in Stock - Ticker Report
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of the firm's stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $23.47, for a total value of $328,580.00. Following the transaction, the chief executive officer now ...
Ticker Report
9/17/2022 Sanjiv Patel Sells 14,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of the stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $23.47, for a total transaction of $328,580.00. Following the completion of the transaction, the chief ...
defenseworld.net
9/16/2022 Sanjiv Patel Sells 14,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 14,000 shares of the firm's stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $23.47, for a total value of $328,580.00. Following the transaction, the chief executive officer now ...
dispatchtribunal.com
8/5/2022 Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate | User Walls
... growing breast cancer portfolio and a regulatory update on RLY-4008 at June 27th analyst and investor event CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today ...
userwalls.news
8/4/2022 Relay Therapeutics Reports Second Quarter 2022 Financial
... look forward to his contributions based on his experiences as a leading academic physician and founder and CEO of an innovative biotechnology company,‚Au said Sanjiv Patel, M.D., Relay Therapeutics‚Ao president and chief executive officer. ‚AuOver the next 12 months, we will continue to build upon our achievements this ...
Globe Newswire
8/4/2022 Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Relay Therapeutics, Inc. Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June 27 th analyst and investor event CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics ...
Yahoo News
8/4/2022 Relay Therapeutics (RLAY) Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
... look forward to his contributions based on his experiences as a leading academic physician and founder and CEO of an innovative biotechnology company,‚Au said Sanjiv Patel, M.D., Relay Therapeutics‚Ao president and chief executive officer. ‚AuOver the next 12 months, we will continue to build upon our achievements this ...
researchpool.com
4/16/2022 Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 28,000 Shares
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 28,000 shares of Relay Therapeutics stock in a transaction on Wednesday, April 13th. The shares were sold at an average price of $31.95, for a total transaction of $894,600.00. Following the sale, the chief executive officer now directly ...
zolmax.com
4/15/2022 Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 28,000 Shares
Relay Therapeutics, Inc. ( NASDAQ:RLAY ‚Ai Get Rating ) CEO Sanjiv Patel sold 28,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $31.95, for a total transaction of $894,600.00. Following the sale, the chief executive ...
etfdailynews.com
8/27/2020 Relay Therapeutics Reports Second Quarter 2020 Financial Results
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported second quarter 2020 financial results. “2020 has been a transformational year thus far for Relay Therapeutics,” said Sanjiv ...
Yahoo News
2/4/2020 Relay Therapeutics Appoints Dr. James Nichols to Lead Expansion into Genetic Diseases
... precision oncology with multiple programs poised to enter the clinic, we are excited to expand the reach of our discovery engine into genetic diseases,” said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics. “I look forward to shaping the company's strategy and approach to genetic diseases and ...
BioSpace
2/4/2020 Relay Therapeutics Appoints Dr. James Nichols to Lead Expansion into Genetic Diseases
Relay Therapeutics , a new breed of company at the intersection of computation and biotechnology, announced today the company's expansion into genetic diseases and the appointment of James Nichols, Ph.D. as Head of Genetic Diseases. Dr. Nichols brings to Relay Therapeutics more than 20 years of experience as a biotech entrepreneur ...
financialbuzz.com
1/6/2020 Relay Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.- Relay Therapeutics , a new breed of company at the intersection of computation and biotechnology, today announced that Sanjiv Patel, M.D., president and chief executive officer, will present an overview of the company's business and scientific objectives at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on ...
Business Wire
11/5/2019 Relay Therapeutics Appoints Human Resources Expert Andy Porter as Executive Vice President and Chief People Officer | Business & Finance | heraldchronicle.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 5, 2019-- Relay Therapeutics , a new breed of company at the intersection of computation and biotechnology, today announced the appointment of Andy Porter as executive vice president and chief people experience officer. Mr. Porter joins Relay Therapeutics from the Broad Institute of MIT and Harvard ...
Business Wire